nt and chief executive officer of NPS, stated:
"After implementing a new business plan in 2007, raising significant
capital and obtaining regulatory clarity from the FDA, NPS now has the
direction, the resources, and the capabilities to develop its products in
specialty indications with high unmet medical needs, including short bowel
syndrome and hypoparathyroidism. With a two to three year cash runway, I am
confident that NPS is well-positioned to advance its pipeline and achieve
commercial success."
2007 Accomplishments
During 2007, NPS reported the following accomplishments:
-- Refocused its business on specialty indications for gastrointestinal
and endocrine disorders with high unmet medical need
-- Raised more than $275.0 million through the issuance of royalty-backed
and convertible notes and the monetization of non-core assets
-- Achieved net operating cash inflow of $27.6 million for 2007 as
compared to a net operating cash outflow of $103.9 for 2006
-- Retired $191.0 million in convertible debt due in 2008
-- Completed a Phase 3 study of GATTEX(TM) (teduglutide) in short bowel
syndrome (SBS) patients who are dependent on parenteral nutrition (PN)
-- Secured an ex-North America partnership for GATTEX with Nycomed
-- Defined a clinical strategy and obtained orphan drug status for NPSP558
(parathyroid hormone 1-84 [rDNA origin injection]) as a potential
therapy for hypoparathyroidism
Francois Nader, M.D., chief executive officer-elect, stated: "We are
committed to executing an ambitious clinical program in 2008. The top-line
results from our Phase 3 extension study of GATTEX in patients with short
bowel syndrome support our plans to initiate a confirmatory Phase 3 study
of GATTEX in this indication in the third quarter of this year. We also
expect to launch a pivotal trial for our PTH 1-84 compound, NPSP558, in
patients with hypoparathy
'/>"/>
SOURCE NPS Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 Related biology technology :1.
Trubion Pharmaceuticals Inc. Reports Fourth-Quarter and Year-Ended 2007 Financial Results and Provides 2008 Financial Outlook2.
ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results3.
Keryx Biopharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference4.
Nventa Biopharmaceuticals Reports Full Year 2007 and Fourth Quarter Financial Results5.
Sagent Pharmaceuticals Launches Cefazolin for Injection, USP6.
Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences7.
Memory Pharmaceuticals Refocuses to Advance Development and Clinical Programs8.
Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference9.
Onyx Pharmaceuticals to Present at Cowen and Company Health Care Conference10.
Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference11.
VIA Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference